Safety evaluation of apremilast for the treatment of psoriasis.
Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017 Jan 30;: Authors: Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L Abstract INTRODUCTION: Psoriasis (PSo) is a chronic inflammatory skin disease associated with co-morbidities such as hypertension, diabetes, dyslipidemia and metabolic syndrome. It is a typothypical Th1/Th17 disease that affects from 2 to 3% of the world population. Numerous are the drugs that can be used in our clinical practice; the choice of these drugs depends on the characteristics of the patient. Areas covered: Apremilast is the first oral small molecules to receive FDA approval for the treatment of adults with active psoriasis and psoriatic arthritis. It is a small-molecule that specifically inhibits the activity of cyclic AMP phosphodiesterase-4 (PDE4). Several analyses have been performed on data from phase III studies to assess apremilast safety and efficacy on psoriasis and psoriatic arthritis (PsA). Apremilast could also represent a treatment opportunity for those patients unresponsive to both systemic and biological agents or whose treatment was contraindicated. Expert opinion: for its safety profile and easy route of administration, apremilast may offer an oral treatment option for those patients that discontinue treatments because of ineffectiveness, intolerability or ineligibility to the currently available drugs. PMID: 28132578 [PubMed - as supplied by publisher]
Middle aortic syndrome is a rare condition characterized by coarctation of distal thoracic or abdominal aorta with involvement of the major branches; therefore, the lesions are particularly difficult to manage. More experience in its treatment is required to establish a well-supported treatment guideline. This retrospective study of the clinical and anatomic characteristics of patients with middle aortic syndrome as well as their treatment details and outcomes was conducted in a single center.
This study aimed to review chara cteristics of multicultural Asian diabetic patients presenting to tertiary care with peripheral vascular complications and subsequent intervention rates and outcomes.
The objective of this study was to review the outcomes after split-thickness skin grafting (SSG) of patients with peripheral artery disease and diabetic foot wounds in an Asian population.
Diabetic foot ulcer (DFU) is a major health problem and remains a major cause of amputation across the world. Critical assessment of the relationship between peripheral artery disease, revascularization, and healing of DFU was performed. A new therapy has been claimed to prevent major amputations in advanced DFU. The intralesional injection of recombinant human epidermal growth factor (EGF) should often lead to satisfactory outcomes. The purpose of our study was to demonstrate the advantage of the combination of revascularization and EGF local infiltration in accelerating healing of DFU.
This report aimed to discuss the reason for IVCT in a case of pregnancy-induced hypertension with decreased antithrombin III and protein S and the anticoagulation strategy.
This study was designed to investigate whether angiogenesis factors could serve as noninvasive markers for the diagnosis of PH in the COPD patient and which could serve as therapeutic targets.
Conclusions: It is very important to study immunologic mechanisms responsible for the presence and severity of psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease and on concomitant disorders. PMID: 30858782 [PubMed]
This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross‐sectional design, patients d iagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [DLQI], 36‐Item Short Form Health Survey [SF‐36] and EuroQol Five‐Dimension Questionnaire Three‐Level version [EQ‐5D‐3L]). Physical examination and several t ests to assess desired outcomes were performed by a dermatologis...
CONCLUSION: Psoriatic arthritis appeared significantly associated with subclinical atherosclerosis and endothelial dysfunction and, in turn, with an increased cardiovascular risk. Thus, patients with psoriatic arthritis may benefit from a periodic assessment of surrogate markers of cardiovascular risk. This could help to establish more specific cardiovascular prevention strategies for these patients. PMID: 29542417 [PubMed - as supplied by publisher]
AbstractPurpose of ReviewA growing body of research highlights the use of TNF inhibitors in the treatment of psoriasis and psoriatic arthritis. We aim to review the literature, compile psoriasis efficacy data for TNF inhibitors, and offer advice regarding the approach to treating this condition.Recent FindingsThe results of randomized placebo-controlled studies indicate that TNF inhibitors are efficacious and well tolerated in the treatment of psoriasis. There is a greater prevalence of anxiety, depression, cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, fatty liver disease, metabolic syndrome, and i...